JP7817743B2 - タンパク質の精製の改善されたプロセス - Google Patents

タンパク質の精製の改善されたプロセス

Info

Publication number
JP7817743B2
JP7817743B2 JP2022566389A JP2022566389A JP7817743B2 JP 7817743 B2 JP7817743 B2 JP 7817743B2 JP 2022566389 A JP2022566389 A JP 2022566389A JP 2022566389 A JP2022566389 A JP 2022566389A JP 7817743 B2 JP7817743 B2 JP 7817743B2
Authority
JP
Japan
Prior art keywords
less
buffer
protein
protein mixture
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022566389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523823A5 (https=
JP2023523823A (ja
Inventor
ナラヤン，オム
クマール グプタ，タルン
タッカー，マヤンククマール
Original Assignee
カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー filed Critical カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー
Publication of JP2023523823A publication Critical patent/JP2023523823A/ja
Publication of JP2023523823A5 publication Critical patent/JP2023523823A5/ja
Priority to JP2025203271A priority Critical patent/JP2026032129A/ja
Application granted granted Critical
Publication of JP7817743B2 publication Critical patent/JP7817743B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022566389A 2020-05-01 2021-05-01 タンパク質の精製の改善されたプロセス Active JP7817743B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203271A JP2026032129A (ja) 2020-05-01 2025-11-25 タンパク質の精製の改善されたプロセス

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN202021018731 2020-05-01
IN202021018735 2020-05-01
IN202021018714 2020-05-01
IN202021018731 2020-05-01
IN202021018735 2020-05-01
IN202021018714 2020-05-01
PCT/IB2021/053658 WO2021220251A1 (en) 2020-05-01 2021-05-01 An improved process of purification of protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203271A Division JP2026032129A (ja) 2020-05-01 2025-11-25 タンパク質の精製の改善されたプロセス

Publications (3)

Publication Number Publication Date
JP2023523823A JP2023523823A (ja) 2023-06-07
JP2023523823A5 JP2023523823A5 (https=) 2024-05-09
JP7817743B2 true JP7817743B2 (ja) 2026-02-19

Family

ID=78373378

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022566389A Active JP7817743B2 (ja) 2020-05-01 2021-05-01 タンパク質の精製の改善されたプロセス
JP2025203271A Pending JP2026032129A (ja) 2020-05-01 2025-11-25 タンパク質の精製の改善されたプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203271A Pending JP2026032129A (ja) 2020-05-01 2025-11-25 タンパク質の精製の改善されたプロセス

Country Status (6)

Country Link
US (6) US20230167153A1 (https=)
EP (1) EP4142792A4 (https=)
JP (2) JP7817743B2 (https=)
AU (1) AU2021262609A1 (https=)
CA (1) CA3182368A1 (https=)
WO (1) WO2021220251A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
WO2023007516A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy’S Laboratories Limited Method to control high molecular weight aggregates in an antibody composition
US20240400612A1 (en) * 2021-09-28 2024-12-05 Kashiv Biosciences, Llc An improved process for purification of fusion protein
WO2023112000A2 (en) * 2021-12-17 2023-06-22 Kashiv Biosciences, Llc An improved method for separation of low molecular weight proteins

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532477A (ja) 2003-10-27 2007-11-15 ワイス ヒドロキシアパタイトクロマトグラフィーを用いる高分子量凝集体の取り出し
JP2008515775A (ja) 2004-08-13 2008-05-15 ワイス 安定化処方
JP2008543881A (ja) 2005-06-17 2008-12-04 エラン ファーマ インターナショナル リミテッド 抗Ａβ抗体を精製する方法
JP2012507550A (ja) 2008-10-31 2012-03-29 ワイス・エルエルシー セラミックヒドロキシアパタイトクロマトグラフィーを使用する酸性タンパク質の精製
JP2018538268A (ja) 2015-11-18 2018-12-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ イオン交換クロマトグラフィーにおける改善されたタンパク質分離
US20190367556A1 (en) 2015-12-21 2019-12-05 Pfizer Inc. Purification of antibody drug conjugates using a sodium phosphate gradient

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328834A (en) 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
CA2259618A1 (en) 1996-07-05 1998-01-15 The Governing Council Of The University Of Toronto Genetic sequences and proteins related to alzheimer's disease, and uses therefor
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002082066A1 (en) 2001-03-28 2002-10-17 Cetek Corporation Concentration and identification of moderate-to-strong hits in natural products by capillary electrophoresis
ES2322945T5 (es) * 2001-12-21 2012-10-17 Immunex Corporation Métodos para purficación de proteína
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
RU2359270C2 (ru) 2003-07-29 2009-06-20 Зольвай Фармасьютиклз Гмбх Способ анализа панкреатита и содержащих его композиций
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
DK1969007T3 (da) 2005-12-20 2013-11-25 Bristol Myers Squibb Co Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
CN101511387A (zh) 2006-09-08 2009-08-19 惠氏公司 使用亲和色谱法纯化蛋白质的精氨酸洗涤液
US20100129379A1 (en) 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
WO2008085988A1 (en) * 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
BRPI0908270A2 (pt) * 2008-02-29 2019-09-10 Biogen Idec Inc proteínas de fusão de imunoglobulinas purificadas e método para a sua purificação
CN102164954B (zh) * 2008-09-23 2018-04-06 弗·哈夫曼-拉罗切有限公司 促红细胞生成素的纯化
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
WO2011067283A1 (en) 2009-12-01 2011-06-09 Novo Nordisk A/S Novel peptidyl alpha-hydroxyglycine alpha-amidating lyases
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
HUE030100T2 (en) 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
WO2011121020A1 (en) 2010-03-30 2011-10-06 Octapharma Ag A process for purifying vitamin k dependent proteins such as coagulation factor ix
KR101976853B1 (ko) 2010-05-25 2019-05-09 제넨테크, 인크. 폴리펩티드의 정제 방법
WO2013071396A1 (en) 2011-11-18 2013-05-23 Université de Montréal Oral leptin formulations and uses thereof
GB2491168B (en) 2011-05-26 2014-09-10 Thermo Electron Mfg Ltd Method and apparatus for improved resolution chromatography
DK2729482T3 (en) 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
SG10201606218WA (en) * 2011-07-29 2016-09-29 Eleven Biotherapeutics Inc Purified Proteins
US9291630B1 (en) 2011-08-29 2016-03-22 Scientific Protein Laboratories, Llc RP-HPLC method for the analysis and quantification of pancreatin active pharmaceutical agents
JP6092892B2 (ja) 2011-12-15 2017-03-08 プレステージ バイオファーマ プライベート リミテッド 抗体の精製方法
AR089434A1 (es) * 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013169338A1 (en) 2012-05-11 2013-11-14 Medimmune, Llc Ctla-4 variants
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
SG11201407809QA (en) * 2012-05-31 2014-12-30 Agency Science Tech & Res Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities
PE20150964A1 (es) 2012-09-07 2015-07-25 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab
SI2895188T1 (en) 2012-09-11 2018-05-31 Coherus Biosciences, Inc. CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
US20150284673A1 (en) 2012-12-13 2015-10-08 Sapphire Energy, Inc. Harvesting algae from water
TWI670279B (zh) * 2013-03-15 2019-09-01 Alder Biopharmaceuticals, Inc. 抗體純化及純度監測
KR101569783B1 (ko) 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
RS57864B1 (sr) 2013-06-17 2018-12-31 De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo Postupci za sprečavanje agregacije virusnih komponenti
CN103405756B (zh) 2013-07-10 2014-12-24 浙江众益制药股份有限公司 药物组合物复方消化酶胶囊(ii)及其制备方法
US20160228371A1 (en) 2013-10-18 2016-08-11 Abbvie Inc. Stable solid units and methods of making the same
CN103667225B (zh) 2013-11-23 2016-08-17 青岛康原药业有限公司 一种制备弹性蛋白酶的方法
PL3116891T3 (pl) 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
WO2016009049A1 (en) 2014-07-18 2016-01-21 Sandoz Ag Methods for purifying tnfr:fc
ES2733298T3 (es) 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
CN107250798A (zh) 2014-12-05 2017-10-13 雀巢产品技术援助有限公司 用于检测患者样品中的生物制品的间接均相迁移率变动试验
KR20180048731A (ko) 2015-08-20 2018-05-10 제넨테크, 인크. 재조합 폴리펩티드를 제조하기 위한 fkpa의 정제 및 그의 용도
ES2979210T3 (es) 2015-12-15 2024-09-24 Oncoc4 Inc Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
EP3436473A4 (en) 2016-03-29 2019-10-23 Navya Biologicals Pvt. Ltd. METHOD FOR PURIFYING FC FUSION PROTEINS
EP3443346B1 (en) 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
TWI734775B (zh) 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
EP4549463A3 (en) * 2016-06-17 2025-07-30 F. Hoffmann-La Roche AG Purification of multispecific antibodies
CN106190935A (zh) 2016-07-13 2016-12-07 江南大学 一种产木聚糖酶的重组菌及其应用
JP7116059B2 (ja) 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
CA3051466A1 (en) 2017-01-31 2018-08-09 Vanderbilt University Generation of human allergen-and helminth-specific ige monoclonal antibodies for diagnostic and therapeutic use
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
PE20200737A1 (es) 2017-06-30 2020-07-23 Spark Therapeutics Inc Metodos de purificacion de columna de vector aav
JP2020531557A (ja) * 2017-08-30 2020-11-05 アレス トレーディング ソシエテ アノニム タンパク質の精製方法
DK3517543T3 (da) 2018-01-30 2020-12-07 Bachem Ag Fremstilling af glucagonpeptider
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
JP7449243B2 (ja) 2018-05-25 2024-03-13 ドクター レディズ ラボラトリーズ リミテッド 安定な融合タンパク質製剤
JP2021525255A (ja) 2018-05-25 2021-09-24 ドクター レディズ ラボラトリーズ リミテッド ＣＴＬＡ４−Ｉｇ融合タンパク質製剤
CN109142728A (zh) 2018-09-04 2019-01-04 深圳市鸿美诊断技术有限公司 一种定量测定粪便中胰弹性蛋白酶1的试剂盒及其应用
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
JP2022531317A (ja) 2019-05-03 2022-07-06 ジェネンテック， インコーポレイテッド 精製プラットフォームから得られた組成物中の酵素加水分解活性速度を低下させる方法
AR119264A1 (es) 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
CA3147265A1 (en) 2019-07-14 2021-01-21 Kashiv Biosciences, Llc A process for separation and quantitation of proteins using capillary electrophoresis
EP4021497B1 (en) 2019-08-30 2026-02-25 Kashiv Biosciences, LLC Novel formulation of highly concentrated pharmacologically active antibody
KR102154952B1 (ko) 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
US20230166200A1 (en) 2020-05-01 2023-06-01 Kashiv Biosciences, Llc An improved process of purification of protein
CA3182315A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of affinity chromatography
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
WO2021240458A2 (en) 2020-05-28 2021-12-02 Kashiv Biosciences, Llc An improved process of storing and preparing the protein
WO2022195505A1 (en) 2021-03-16 2022-09-22 Kashiv Biosciences, Llc Novel formulation of fusion protein
CA3188632A1 (en) 2021-03-23 2022-09-29 Kashiv Biosciences, Llc An extraction process of pancrelipase and evaluation threof
CA3176410A1 (en) 2021-09-24 2023-03-24 Kashiv Biosciences, Llc An improved process for preparation of stable protein solution
US20240400612A1 (en) 2021-09-28 2024-12-05 Kashiv Biosciences, Llc An improved process for purification of fusion protein
AU2022358612A1 (en) 2021-09-28 2024-04-11 Kashiv Biosciences, Llc An improved process of purification of fusion protein
EP4408856A4 (en) 2021-09-28 2025-11-12 Kashiv Biosciences Llc IMPROVED PROCESS FOR PROTEIN PURIFICATION
AU2022359021A1 (en) 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
EP4392156A4 (en) 2021-10-08 2025-06-25 Kashiv Biosciences, LLC Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023112000A2 (en) 2021-12-17 2023-06-22 Kashiv Biosciences, Llc An improved method for separation of low molecular weight proteins
CA3255003A1 (en) 2022-03-23 2023-09-28 Kashiv Biosciences, Llc IMPROVED METHOD FOR SEPARATION AND ANALYSIS OF PANCREATIC ENZYMES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007532477A (ja) 2003-10-27 2007-11-15 ワイス ヒドロキシアパタイトクロマトグラフィーを用いる高分子量凝集体の取り出し
JP2008515775A (ja) 2004-08-13 2008-05-15 ワイス 安定化処方
JP2008543881A (ja) 2005-06-17 2008-12-04 エラン ファーマ インターナショナル リミテッド 抗Ａβ抗体を精製する方法
JP2012507550A (ja) 2008-10-31 2012-03-29 ワイス・エルエルシー セラミックヒドロキシアパタイトクロマトグラフィーを使用する酸性タンパク質の精製
JP2018538268A (ja) 2015-11-18 2018-12-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ イオン交換クロマトグラフィーにおける改善されたタンパク質分離
US20190367556A1 (en) 2015-12-21 2019-12-05 Pfizer Inc. Purification of antibody drug conjugates using a sodium phosphate gradient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Stephan M. KOZA，Size-Exclusion Ultra Performance Liquid Chromatography Method Development for the Analysis of the Degradation Products of the Trastuzumab Antibody，Waters Corporation, [online]，2012年，pp. 1-14，<https://www.waters.com/content/dam/waters/en/app-notes/2012/720004416/720004416-en.pdf>，[retrieved on 2025.06.16]
モノクローナル抗体および抗体薬複合体のサイズ排除クロマトグラフィー分析，Agilent AdvanceBio SEC 200Å 1.9 μm カラム, [online]，2019年，pp. 1-4，<https://www.chem-agilent.com/appnote/pdf/low_5994-0827JAJP.pdf>，[retrieved on 2025.06.16]

Also Published As

Publication number Publication date
WO2021220251A1 (en) 2021-11-04
US12378282B2 (en) 2025-08-05
US12600747B2 (en) 2026-04-14
US20250282814A1 (en) 2025-09-11
EP4142792A4 (en) 2024-11-27
JP2026032129A (ja) 2026-02-25
EP4142792A1 (en) 2023-03-08
US20240158437A1 (en) 2024-05-16
US20250011395A1 (en) 2025-01-09
AU2021262609A1 (en) 2022-12-22
US12435106B2 (en) 2025-10-07
CA3182368A1 (en) 2021-11-04
JP2023523823A (ja) 2023-06-07
US20250353877A1 (en) 2025-11-20
US12139510B2 (en) 2024-11-12
US20230167153A1 (en) 2023-06-01
US20240239838A1 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
JP7817743B2 (ja) タンパク質の精製の改善されたプロセス
KR101683415B1 (ko) 단일클론항체에 대한 정제 방법
JP7624414B2 (ja) 抗α４β７抗体の産生方法
TW201425331A (zh) 高純度及優良產量之正確折疊之恩博（ｅｔａｎｅｒｃｅｐｔ）
CN105121469A (zh) 用于增加蛋白质的焦谷氨酸形成的方法
US20250296014A1 (en) An improved process of purification of protein
US20240343758A1 (en) Process for purification of protein
CN106414495A (zh) 抗体处理方法
US20250099873A1 (en) Process of affinity chromatography
US20260116917A1 (en) Process of purification of protein
US20250296015A1 (en) An improved process of purification of protein
US20260117000A1 (en) Process of purification of protein
US20260103542A1 (en) Process of purification of protein
WO2022245306A1 (en) Protein purification by affinity chromatography

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20251125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260130

R150 Certificate of patent or registration of utility model

Ref document number: 7817743

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150